Julieta Rodriguez, Capucine Baldini, Arnaud Bayle, Arnaud Pages, François Xavier Danlos, Damien Vasseur, Etienne Rouleau, Ludovic Lacroix, Beatriz Alonso de Castro, Vincent Goldschmidt, Lauren Seknazi, Antoine Hollebecque, Jean-Marie Michot, Stephane Champiat, Aurelien Marabelle, Kaissa Ouali, Christophe Marzac, Santiago Ponce, Jean-Baptiste Micol, Nathalie Chaput, Christophe Massard, Antoine Italiano
PURPOSE: With liquid biopsy's widespread adoption in oncology, an increased number of clonal hematopoiesis-associated mutations (CHm) have been identified in patients with solid tumors. However, its impact on patient outcomes remains unclear. This study aimed to analyze and describe CHm in a cohort of phase I patients. METHODS: Retrospective data collection from medical records and molecular profiles (Foundation One Liquid CDx Assay) was performed before first study drug administration at the Drug Development Department of Gustave Roussy (France) within the STING trial (ClinicalTrials...
May 2024: JCO Precision Oncology